Sulphonylurea monotherapy for patients with type 2 diabetes mellitus-Reference-Cited by-同舟云学术

Sulphonylurea monotherapy for patients with type 2 diabetes mellitus

Published:2015-07-29 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Hemmingsen Bianca¹,Schroll Jeppe B²,Lund Søren S³,Wetterslev Jørn¹,Gluud Christian⁴,Vaag Allan⁵,Sonne David Peick⁶,Lundstrøm Lars H⁷,Almdal Thomas P⁸

Affiliation:

1. Department 7812, Rigshospitalet, Copenhagen University Hospital; Copenhagen Trial Unit, Centre for Clinical Intervention Research; Blegdamsvej 9 Copenhagen Denmark DK-2100

2. Rigshospitalet; Nordic Cochrane Center; Blegdamsvej 9 København Denmark 2100

3. Boehringer Ingelheim Pharma GmbH & Co. KG; Ingelheim Germany

4. Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital; The Cochrane Hepato-Biliary Group; Blegdamsvej 9 Copenhagen Denmark DK-2100

5. Rigshospitalet and Copenhagen University; Department of Endocrinology, Diabetes and Metabolism; Afsnit 7652 København N Denmark 2200

6. Gentofte Hospital, University of Copenhagen; Department of Internal Medicine F; Niels Andersens Vej 65 Hellerup Denmark 2900

7. Hillerød Hospital; Department of Anaesthesiology; Dyrehavevej 29 Hillerød Denmark 3400

8. Copenhagen University Hospital Gentofte; Department of Medicine F; Hellerup Denmark 2900

Publisher

Wiley

Subject

Pharmacology (medical)

Reference300 articles.

1. Postprandial plasma glucose excursions and cognitive functioning in aged type 2 diabetics;Abbatecola;Neurology,2006

2. GlaxoSmithKline Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide ClinicalTrials.gov 2006

3. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials;Home;Diabetologia,2010

4. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8];Kahn;New England Journal of Medicine,2006

5. Cardiovascular safety of rosiglitazone;Krall;Lancet,2007

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Loureirin B promotes insulin secretion through GLP-1R and AKT/PDX1 pathways;European Journal of Pharmacology;2022-12